146 related articles for article (PubMed ID: 36905668)
1. Efficacy and safety of bevacizumab, irinotecan, and temozolomide combination for relapsed or refractory pediatric central nervous system embryonal tumor: a single-institution study.
Shiba Y; Motomura K; Taniguchi R; Kurimoto M; Mizutani K; Ohka F; Aoki K; Ito E; Nishikawa T; Yamaguchi J; Kibe Y; Shimizu H; Maeda S; Nakashima T; Suzuki H; Muramatsu H; Takahashi Y; Saito R
J Neurosurg Pediatr; 2023 Mar; ():1-9. PubMed ID: 36905668
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Wang CH; Hsu TR; Wong TT; Chang KP
Childs Nerv Syst; 2009 May; 25(5):535-41. PubMed ID: 19107490
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
Levy AS; Krailo M; Chi S; Villaluna D; Springer L; Williams-Hughes C; Fouladi M; Gajjar A
Pediatr Blood Cancer; 2021 Aug; 68(8):e29031. PubMed ID: 33844469
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
5. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.
Metts J; Harrington B; Salman E; Bradfield SM; Flanary J; Mosha M; Amankwah E; Stapleton S
Childs Nerv Syst; 2022 May; 38(5):919-928. PubMed ID: 35260913
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of Outcomes by Treatment Regimen and Histology in Central Nervous System Primary Embryonal Tumors.
Bhimani AD; Ryoo JS; Reddy AK; Denyer S; McGuire LS; Alonso M; Mehta AI
World Neurosurg; 2020 Sep; 141():e289-e306. PubMed ID: 32434022
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
11. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Lu G; Zhu P; Rao M; Linendoll N; Buja LM; Bhattacharjee MB; Brown RE; Ballester LY; Tian X; Pilichowska M; Wu JK; Hergenroeder GW; Glass WF; Chen L; Zhang R; Pillai AK; Hunter RL; Zhu JJ
J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
13. Relapse patterns in pediatric embryonal central nervous system tumors.
Perreault S; Lober RM; Carret AS; Zhang G; Hershon L; Décarie JC; Yeom K; Vogel H; Fisher PG; Partap S
J Neurooncol; 2013 Nov; 115(2):209-15. PubMed ID: 23921420
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
15. Embryonal tumors in the WHO CNS5 classification: A Review.
Gianno F; Miele E; Antonelli M; Giangaspero F
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S73-S82. PubMed ID: 35562137
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
Fouladi M; Blaney SM; Poussaint TY; Freeman BB; McLendon R; Fuller C; Adesina AM; Hancock ML; Danks MK; Stewart C; Boyett JM; Gajjar A
Cancer; 2006 Nov; 107(9):2291-7. PubMed ID: 17019740
[TBL] [Abstract][Full Text] [Related]
17. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience.
Bernstock JD; Alva E; Cohen JL; Lobbous M; Chagoya G; Elsayed GA; Orr BA; Rozzelle C; Rocque B; Blount J; Johnston JM; Li R; Fiveash JB; Dhall G; Reddy AT; Friedman GK
Pediatr Blood Cancer; 2020 Mar; 67(3):e28119. PubMed ID: 31850678
[TBL] [Abstract][Full Text] [Related]
19. Embryonal Tumors of the Central Nervous System: An Update.
Blessing MM; Alexandrescu S
Surg Pathol Clin; 2020 Jun; 13(2):235-247. PubMed ID: 32389264
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
